The invitro and invivo profile of aclidinium bromide in comparison with glycopyrronium bromide

Pulmonary Pharmacology and Therapeutics

Volumn 28, Issue 2, 2014, Pages 114-121

  Gavaldà, Amadeu ^a   Ramos, Israel ^a   Carcasona, Carla ^a   Calama, Elena ^a   Otal, Raquel ^a   Montero, José Luis ^a   Sentellas, Sonia ^a   Aparici, Monica ^a   Vilella, Dolors ^a   Alberti, Joan ^a   Beleta, Jorge ^a   Miralpeix, Montserrat ^a  

^a Almirall Prodesfarma S A   (Spain)

Author keywords

Aclidinium; Aclidinium bromide (PubChem CID: 11519741); COPD; Glycopyrronium; Glycopyrronium bromide (PubChem CID: 11693); Ipratropium bromide (PubChem CID: 31098); LAMA; Long acting muscarinic antagonists; Muscarinic receptors; Preclinical; Raw; SAMA; Tiotropium bromide (PubChem CID: 5487426)

Indexed keywords

ACLIDINIUM BROMIDE; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; TIOTROPIUM BROMIDE; ACETYLCHOLINE; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE DERIVATIVE; TROPANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHOCONSTRICTION; BRONCHODILATATION; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; GUINEA PIG; HUMAN; HYDROLYSIS; HYPERSALIVATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; SALIVATION; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; HALF LIFE TIME; SPECIES DIFFERENCE; TIME; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; GLYCOPYRROLATE; GUINEA PIGS; HALF-LIFE; HUMANS; HYDROLYSIS; IPRATROPIUM; MALE; MUSCARINIC ANTAGONISTS; RATS; RATS, WISTAR; SCOPOLAMINE DERIVATIVES; SPECIES SPECIFICITY; TIME FACTORS; TROPANES;

EID: 84904128446     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.05.005     Document Type: Article

References (39)

1. Vestbo J., Hurd S.S., Agustí A.G., Jones P.W., Vogelmeier C., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2013, 187:347-365.
2. Gosens R., Zaagsma J., Meurs H., Halayko A.J. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006, 7:73.
3. Canning B.J. Reflex regulation of airway smooth muscle tone. JAppl Physiol 2006, 101:971-985.
4. Rogers D.F. Motor control of airway goblet cells and glands. Respir Physiol 2001, 125:129-144.
5. Rogers D.F. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol 2002, 2:249-255.
6. Barnes P.J. Rationale for the use of antimuscarinics in obstructive airway disease. Rev Contemp Pharmacother 1992, 3:173-182.
7. Barnes P.J. Muscarinic receptor subtypes in airways. Life Sci 1993, 52:521-527.
8. Roffel A.F., Elzinga C.R., Zaagsma J. Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990, 3:47-51.
9. Fisher J.T., Vincent S.G., Gomeza J., Yamada M., Wess J. Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J 2004, 18:711-713.
10. Tobin G., Ryberg A.T., Gentle S., Edwards A.V. Distribution and function of muscarinic receptor subtypes in the ovine submandibular gland. JAppl Physiol 2006, 100:1215-1223.
11. National Institute for Health and Clinical Excellence NICE Clinical Guideline 101, Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update) 2010, [Internet], [cited 2013 August 16]. Available from:. http://www.nice.org.uk/guidance/CG101.
12. Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006, 61:854-862.
13. van Noord J.A., Bantje T.A., Eland M.E., Korducki L., Cornelissen P.J. Arandomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000, 55:289-294.
14. Ogale S.S., Lee T.A., Au D.H., Boudreau D.M., Sullivan S.D. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010, 137:13-19.
15. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:1439-1450.
16. Singh S., Loke Y.K., Enright P.L., Furberg C.D. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011, 342:d3215.
17. ® (aclidinium bromide) 2013, [Internet], [cited 2013 March 28]. Available from:. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002211/human_med_001571.jsp%26mid=WC0b01ac058001d124.
18. ® as maintenance COPD treatment in the EU 2012, [Internet], [cited 2013 March 28]. [Available from:]. http://www.novartis.com/newsroom/media-releases/en/2012/1645116.shtml.
19. Food and Drug Administration Tudorza™ Pressair™ (aclidinium bromide) 2012, [Internet], [cited 2013 March 28]. Available from:. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
20. Gavaldà A., Miralpeix M., Ramos I., Otal R., Carreño C., Viñals M., et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. JPharmacol Exp Ther 2009, 331:740-751.
21. Casarosa P., Bouyssou T., Germeyer S., Schnapp A., Gantner F., Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. JPharmacol Exp Ther 2009, 330:660-668.
22. Sentellas S., Ramos I., Albertí J., Salvà M., Antón F., Miralpeix M., et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: invitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010, 39:283-290.
23. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
24. Cortijo J., Sanz C.M., Villagrasa V., Morcillo E.J., Small R.C. The effects of phorbol 12,13-diacetate on responses of guinea-pig isolated trachea to methylxanthines, isoprenaline and ryanodine. Br J Pharmacol 1994, 111:769-776.
25. Haddad E.B., Patel H., Keeling J.E., Yacoub M.H., Barnes P.J., Belvisi M.G. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol 1999, 127:413-420.
26. Disse B., Reichl R., Speck G., Traunecker W., Ludwig Rominger K.L., Hammer R. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 1993, 52:537-544.
27. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A4-year trial of tiotropium in chronic obstructive pulmonary disease. NEngl J Med 2008, 359:1543-1554.
28. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San Pedro G., ZuWallack R.L., et al. Along-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224.
29. Kerwin E.M., D'Urzo A.D., Gelb A.F., Lakkis H., Garcia Gil E., Caracta C.F., et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012, 9:90-101.
30. Jones P.W., Singh D., Bateman E.D., Agusti A., Lamarca R., de Miquel G., et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012, 40:830-836.
31. Kerwin E., Hébert J., Gallagher N., Martin C., Overend T., Alagappan V.K., et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012, 40:1106-1114.
32. D'Urzo A., Ferguson G.T., van Noord J.A., Hirata K., Martin C., Horton R., et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:156.
33. Beeh K.M., Wagner F., Khindri S., Drollmann A.F. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011, 8:340-345.
34. Sykes D.A., Dowling M.R., Leighton-Davies J., Kent T.C., Fawcett L., Renard E., et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. JPharmacol Exp Ther 2012, 343:520-528.
35. Brodde O.E., Michel M.C. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999, 51:651-690.
36. Verkindre C., Fukuchi Y., Flémale A., Takeda A., Overend T., Prasad N., et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010, 104:1482-1489.
37. Fuhr R., Magnussen H., Sarem K., Llovera A.R., Kirsten A.M., Falqués M., et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012, 141:745-752.
38. Jansat J.M., Lamarca R., de Miquel G., Schrödter A., Miletzki B., Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. JClin Pharmacol 2009, 49:1239-1246.
39. Jansat J.M., Lamarca R., Garcia Gil E., Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009, 47:460-468.